| Share this on: |  |
 delicious |
|
 Digg |
|
 Facebook |
|
 LinkedIn |
|
 Twitter |
|
 Yahoo! Buzz |
|
 |
|
| What is this? | |
Investors
Horizon Pharma is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. Horizon Pharma is headquartered in Northbrook, IL.
View all 
Recent Releases
Horizon Pharma Announces First Quarter 2012 Financial Results
DEERFIELD, IL -- (Marketwire) -- 05/10/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the first quarter ended March 31, 2012.
DUEXIS®/RAYOS® Highlights
DUEXIS, the Company's proprietary single-tablet combination of ibuprofen and famotidine, was launched in December 2011 with sampling and initial physician detailing, and fully launched in January 2012 following the Company's national sales launch meeting.
Initial feedback from physicians, managed care access and ini...
Read more »
Annals of the Rheumatic Diseases Publishes Pivotal Phase 3 Study Demonstrating Efficacy and Safety of RAYOS(R) (Delayed-Release Prednisone) in Combination With DMARD Therapy in Rheumatoid Arthritis Patients
DEERFIELD, IL -- (Marketwire) -- 05/07/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the Annals of the Rheumatic Diseases has published results from the CAPRA-2 (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) U.S. registration study, which demonstrated that patients with active rheumatoid arthritis (RA) treated with RAYOS® in addition to ongoing disease-modifying anti-rheumatic drug (DMARD) therapy experienced a statistically significant improvement in American College of Rheumatology (ACR) response criteria compared to placebo plus DMARD therapy. ...
Read more »
Horizon Pharma to Present at the 11th Annual JMP Securities Research Conference
DEERFIELD, IL -- (Marketwire) -- 05/02/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the JMP Securities Research Conference on Monday, May 14, 2012 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern time) in San Francisco, CA. Mr. Walbert will provide an overview of the Company and its corporate activities.
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available for 10 busi...
Read more »
Horizon Pharma to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results on May 10, 2012
DEERFIELD, IL -- (Marketwire) -- 05/01/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that its first quarter 2012 financial results will be released on Thursday, May 10, 2012. Following the announcement, Horizon's management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company's financial and operating results and provide a general business update.
The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to th...
Read more »
Horizon Pharma Files Patent Infringement Lawsuit Against Par Pharmaceutical, Inc. for Filing an ANDA Against DUEXIS(R)
DEERFIELD, IL -- (Marketwire) -- 03/28/12 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Par Pharmaceutical, Inc. ("Par") and related to an Abbreviated New Drug Application ("ANDA") that Par filed with the U.S. Food and Drug Administration ("FDA") to market a generic version of DUEXIS® tablets.
The lawsuit claims infringement of Horizon's US patent 8,067,033 that is listed in the FDA's Orange Book and expires July 18, 2026. Horizon received a Para...
Read more »